BriaCell Presents Clinical Data at 2021 Keystone Symposium
January 26 2021 - 5:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT)
(OTCQB:BCTXF),
a clinical-stage
biotechnology company specializing in targeted immunotherapies for
advanced breast cancer, is pleased to announce the presentation of
results from clinical studies with its lead product candidate,
Bria-IMT™, summarized in a poster session held January 25-27 during
the 2021 Keystone Symposium, “Emerging Cell Therapies: Realizing
the Vision of NextGen Cell Therapeutics,” a virtual scientific
conference.
Overall, the data
suggests a potentially significant survival benefit for the
patients treated with the Bria-IMT™ regimen alone or in combination
with checkpoint inhibitors, especially in those with moderately or
well differentiated tumors or those who match Bria-IMT™ at 2 HLA
alleles. We hypothesize that Bria-IMT™, with a molecular signature
most closely related to moderately or well differentiated tumors,
may result in disease control especially in patients with
moderately-well differentiated tumors. The patient data
summarized and discussed belong to previously-disclosed patients
(i.e., no incremental numbers enrolled).
Dr. Bill Williams, BriaCell’s President &
CEO, presented the clinical and pathological data of Bria-IMT™
monotherapy (i.e., the Bria-IMT™ regimen alone) and Bria-IMT™ in
combination with immune checkpoint inhibitors including
pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.),
and more recently, Incyte’s INCMGA00012 (under a corporate
collaboration with Incyte Corporation), in advanced breast
cancer.
Details and results on the poster presentation
are summarized below:
Poster Title:
Personalized off-the-shelf whole cell immunotherapy for cancer
Monotherapy Study – 27
patients: The patients were heavily pre-treated (median of
5 prior therapy regimens). Disease control including stable disease
(SD), partial responses (PR) or complete responses (CR) was seen in
8 patients (30%) suggesting clinical benefit. Importantly, disease
control was more frequent in patients who had 2 or more HLA matches
with Bria-IMT™ (67%) or had moderately or well differentiated
tumors (63%) suggesting the potential importance of these factors
in designing the next generation of personalized
immunotherapies.
Combination Study – 12 patients
(Bria-IMT™ regimen with checkpoint inhibitors): The
patients were heavily pre-treated (median of 6 prior therapy
regimens). Disease control was seen in 4 patients (33%).
Importantly, patients with moderately or well differentiated tumors
were more likely to achieve disease control (3/4, 75%) suggesting
clinical benefit in this subset of patients. Furthermore, the data
suggests the potential additive or synergistic effects of check
point inhibitors when combined with the Bria-IMT™ regimen.
Patients with moderately or well
differentiated tumors: The patients with moderately or
well differentiated tumors (monotherapy and combination therapy
studies combined) were heavily pre-treated (median of 8 prior
therapy regimens). Disease control was seen in 7 of 11 patients
(64%) suggesting clinical benefit in this subset of patients. This
included 2 of 5 patients with objective responses, both of whom had
2 or more HLA matches with Bria-IMT™. Overall survival (OS),
collected in 6 patients, was 12.5 months suggesting clinical
benefit. In comparison, an OS of 7.2-9.8 months was reported in
similar patients in the third line setting (Kazmi S, et al., Breast
Cancer Res Treat. 2020).
Capitalizing on these
findings, BriaCell has engineered cell lines to express specific
HLA alleles allowing a single HLA match with ~99% and a double HLA
match with ~90% of the population. These cell lines will provide a
personalized approach to cancer immunotherapy that is
pre-manufactured rather than prepared individually per patient,
eliminating the time and complex manufacturing logistics of other
personalized immunotherapies.
A copy of the poster will be posted at the
following: https://briacell.com/novel-technology/scientific-publications/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding
Forward-Looking Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024